Atropine eye drops to reduce pain and posterior synechiae after vitrectomy
APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes
We will test whether atropine 1% eye drops used after vitrectomy surgery reduce pain and lower the chance of posterior synechiae.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 62 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT07434635 on ClinicalTrials.gov |
What this trial studies
This Phase 4 interventional study compares postoperative outcomes in patients undergoing vitrectomy who receive atropine 1% eye drops versus those who do not. Eligible participants must be able to give informed consent and cannot be on postoperative topical nonsteroidal anti-inflammatory drugs or have an altered anti-inflammatory drop schedule; patients with a documented atropine allergy are excluded. Investigators will monitor postoperative pain, the development of posterior synechiae, and routine recovery measures following surgery. The study is conducted at the University of California, San Francisco and follows patients through the standard postoperative period.
Who should consider this trial
Good fit: Ideal candidates are patients undergoing vitrectomy who can give informed consent and are not using postoperative topical NSAIDs or altered anti-inflammatory regimens and who are not allergic to atropine.
Not a fit: Patients who are prescribed postoperative topical nonsteroidal anti-inflammatory drugs, require altered anti-inflammatory schedules, or have an atropine allergy are excluded and may not receive benefit from this approach.
Why it matters
Potential benefit: If successful, atropine could reduce postoperative pain and lower the incidence of posterior synechiae, improving recovery after vitrectomy.
How similar studies have performed: Atropine is commonly used after eye surgery but high-quality comparative data are limited, so this trial adds to mixed existing evidence on its benefits.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient undergoing vitrectomy surgery * able to give informed consent Exclusion Criteria: * post-operative eyedrop regimens that include topical non steroidal anti-inflammatory medications * subjects with altered post-operative eyedrop schedule for enhanced inflammation control * documented allergy to atropine
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Jay Stewart, MD — University of California, San Francisco
- Study coordinator: Jay Stewart, MD
- Email: eyestudy@ucsf.edu
- Phone: 415-353-9635
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.